Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly oral islatravir + lenacapavir in virologically suppressed HIV-1
NCT05052996Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of islatravir, lenacapavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Oct 2021; status: active, not recruiting.
02
Drugs
islatravirlenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05052996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052996.